TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology…
Month: September 2022
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology…
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg…
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg…
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg…
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical…
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical…
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical…
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and…
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and…
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and…
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
– The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended…
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
– The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended…
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
– The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended…
Celularity to Present at Jefferies Cell and Genetic Medicine Summit
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…
Celularity to Present at Jefferies Cell and Genetic Medicine Summit
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…
Celularity to Present at Jefferies Cell and Genetic Medicine Summit
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…